ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines and interferons"

  • Abstract Number: 2023 • 2018 ACR/ARHP Annual Meeting

    Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases

    Adriana Almeida de Jesus1, Yanfeng Hou2, Louise Malle3, Scott Canna4, Gina A. Montealegre Sanchez1, Hanna Kim5, Rachel VanTries1, Seza Ozen6, Samantha Dill7, Dawn C. Chapelle7, Bernadette Marrero1, Yan Huang1, Angelique Biancotto8 and Raphaela Goldbach-Mansky1, 1Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, 2Department of Rheumatology, Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4RK Mellon Institute for Pediatric Research, University of Pittsburgh/Children's Hospital of Pittsburgh of UPMC, Pittsburrgh, PA, 5Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, 6Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 7Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 8Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD

    Background/Purpose: Many infants and children with early-onset autoinflammatory diseases are mutation-negative for genetically known autoinflammatory diseases. Recent data suggest a role for Type-I interferon dysregulation…
  • Abstract Number: 1658 • 2017 ACR/ARHP Annual Meeting

    Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways

    Rufei Lu1, Cristina Arriens2, Teresa Aberle3, Stan Kamp3, Melissa E. Munroe3, Tim Gross1, Wade DeJager3, Susan Macwana3, Virginia C. Roberts3, Stephen Apel4, Hua Chen3, Eliza Chakravarty5, Katherine Thanou3, Joan T. Merrill6 and Judith A. James7, 1Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical research af, Edmond, OK, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and…
  • Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting

    B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers

    Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
  • Abstract Number: 1859 • 2015 ACR/ARHP Annual Meeting

    Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions

    Sarthak Gupta1,2, Ioanna P. Tatouli3, Lindsey B. Rosen1, Sarfaraz Hasni2, Illias Alevizos4, Zerai G. Manna2, Juan Rivera2, Chao Jiang2,5, Richard M. Siegel6, Steven M. Holland1, Haralampos M. Moutsopoulos3 and Sarah K. Browne1,7, 1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 4National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 5National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD, 6NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, 7Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, a systematic investigation of their presence and significance in autoimmune diseases is…
  • Abstract Number: 1656 • 2013 ACR/ARHP Annual Meeting

    Interferon Type I and T Helper 17: A Dangerous Liaison In Primary Sjögren’s Syndrome?

    Zana Brkic1, Sandra M.J. Paulissen2, Cornelia G. van Helden-Meeuwsen3, Naomi I. Maria3, Odilia B.J. Corneth4, Nadine Davelaar5, Jan Piet van Hamburg5, Paul L. Van Daele3, Virgil A. Dalm1, Martin van Hagen3, Erik Lubberts6 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 5Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

    Background/Purpose: The T helper 17 (Th17) cell subset, which produces IL-17A, IL-17F, IL-22 and IL-21, has been implicated in the pathogenesis of primary Sjögren’s syndrome…
  • Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting

    T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?

    Odilia B.J. Corneth1, Zana Brkic2, Cornelia G. van Helden-Meeuwsen3, Radboud J.E.M. Dolhain4, Naomi I. Maria3, Sandra M.J. Paulissen4, Nadine Davelaar5, Jan Piet van Hamburg5, Paul L. Van Daele3, Virgil A. Dalm2, Martin van Hagen3, Marjan A. Versnel2 and Erik Lubberts6, 1Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 5Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

    Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology